| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.048 | 0.5 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.5 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.11 | 0.5 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.5 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.5 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.5 |